Event

Infection with Mycobacterium tuberculosis (Mtb) is often categorized as either "active" or "latent." However, it is increasingly clear that infection with Mtb results in a much broader range of clinically relevant outcomes. Understanding the molecular and immunologic basis of this spectrum of infection is clinically relevant, as identifying those at risk for progression to disease following infection has the potential to facilitate the eradication of TB worldwide.